Serum Soluble Interleukin 6 (IL-6) Receptor and IL-6/soluble IL-6 Receptor Complex in Systemic Juvenile Rheumatoid Arthritis

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1994 May 1

PMID 8182142

Citations 56

Authors

F De Benedetti

M Massa

P Pignatti

S Albani

D Novick

A Martini

Affiliations

Soon will be listed here.

Abstract

By using a sandwich ELISA, soluble human IL-6 receptor (sIL-6 R) levels were measured in the sera of 20 healthy children and of 25 patients with systemic juvenile rheumatoid arthritis (JRA). In patients with systemic JRA, serum sIL-6 R levels (114.6 +/- 37.7 ng/ml) were significantly lower (P < 0.01) than those of healthy children (161.2 +/- 45.5 ng/ml). Serum sIL-6 R levels were negatively correlated (r = -0.610, P < 0.001) with serum IL-6 levels measured with the B9 cells. The serum IL-6/sIL-6 R complex was detected using an ELISA based on a monoclonal antibody to IL-6 for capture and on a monoclonal antibody to human sIL-6 R for detection. Healthy controls had little, if any, detectable serum IL-6/sIL-6 R complex (OD 0.024 +/- 0.027), while the majority of patients with systemic JRA presented measurable serum IL-6/sIL-6 R complex (OD 0.492 +/- 0.546). IL-6 levels estimated in the circulating IL-6/sIL-6 R complexes were in the range of nanograms per milliliter and approximately 20-fold higher than those measured by the B9 cells. Since serum C-reactive protein concentrations were much more correlated with serum levels of IL-6/sIL-6 R complexes (r = 0.713, r2 = 0.51, P < 0.0001) than with the serum IL-6 levels measured with the B9 cells (r = 0.435, r2 = 0.19, P = 0.05), the large quantities of serum IL-6 present in IL-6/sIL-6 R complexes appear to be biologically relevant in vivo, at least as far as the induction by IL-6 of acute phase protein production.

Citing Articles

Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease.

Bindoli S, De Matteis A, Mitrovic S, Fautrel B, Carmona L, De Benedetti F Ann Rheum Dis. 2024; 83(12):1731-1747.

PMID: 39317415 PMC: 11671904. DOI: 10.1136/ard-2024-225854.

CXCL10 as a shared specific marker in rheumatoid arthritis and inflammatory bowel disease and a clue involved in the mechanism of intestinal flora in rheumatoid arthritis.

Guan Y, Zhang Y, Zhu Y, Wang Y Sci Rep. 2023; 13(1):9754.

PMID: 37328529 PMC: 10276029. DOI: 10.1038/s41598-023-36833-7.

Immunoprofiling of active and inactive systemic juvenile idiopathic arthritis reveals distinct biomarkers: a single-center study.

Qu H, Sundberg E, Aulin C, Neog M, Palmblad K, Horne A Pediatr Rheumatol Online J. 2021; 19(1):173.

PMID: 34963488 PMC: 8713412. DOI: 10.1186/s12969-021-00660-9.

A nomogram to predict the risk of prolonged length of stay following primary total hip arthroplasty with an enhanced recovery after surgery program.

Wang H, Fan T, Li W, Yang B, Lin Q, Yang M J Orthop Surg Res. 2021; 16(1):716.

PMID: 34906186 PMC: 8672506. DOI: 10.1186/s13018-021-02877-6.

Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease.

Yan X, Tang W, Zhang Z, Zhang Y, Luo C, Tang X Front Pediatr. 2021; 9:735846.

PMID: 34820342 PMC: 8606744. DOI: 10.3389/fped.2021.735846.

References

BREWER Jr E, Bass J, Baum J, Cassidy J, Fink C, Jacobs J . Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum. 1977; 20(2 Suppl):195-9. View

Yawata H, Yasukawa K, Natsuka S, Murakami M, Yamasaki K, Hibi M . Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130. EMBO J. 1993; 12(4):1705-12. PMC: 413384. DOI: 10.1002/j.1460-2075.1993.tb05815.x. View

Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B . Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988; 241(4867):825-8. DOI: 10.1126/science.3136546. View

Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B . Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988; 18(11):1797-801. DOI: 10.1002/eji.1830181122. View

Helfgott D, Tatter S, Santhanam U, Clarick R, Bhardwaj N, May L . Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection. J Immunol. 1989; 142(3):948-53. View

Jablons D, Mule J, McIntosh J, Sehgal P, May L, Huang C . IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol. 1989; 142(5):1542-7. View

Fong Y, Moldawer L, Marano M, Wei H, Tatter S, Clarick R . Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol. 1989; 142(7):2321-4. View

Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T . Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989; 58(3):573-81. DOI: 10.1016/0092-8674(89)90438-8. View

Novick D, Engelmann H, Wallach D, Rubinstein M . Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989; 170(4):1409-14. PMC: 2189483. DOI: 10.1084/jem.170.4.1409. View

10.

Novick D, Eshhar Z, Revel M, Mory Y . Monoclonal antibodies for affinity purification of IL-6/IFN- beta 2 and for neutralization of HGF activity. Hybridoma. 1989; 8(5):561-7. DOI: 10.1089/hyb.1989.8.561. View

11.

Bataille R, Jourdan M, Zhang X, Klein B . Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 1989; 84(6):2008-11. PMC: 304085. DOI: 10.1172/JCI114392. View

12.

Van Snick J . Interleukin-6: an overview. Annu Rev Immunol. 1990; 8:253-78. DOI: 10.1146/annurev.iy.08.040190.001345. View

13.

Novick D, Engelmann H, Wallach D, Leitner O, Revel M, Rubinstein M . Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr. 1990; 510:331-7. DOI: 10.1016/s0021-9673(01)93767-7. View

14.

Honda M, Kitamura K, Mizutani Y, Oishi M, Arai M, Okura T . Quantitative analysis of serum IL-6 and its correlation with increased levels of serum IL-2R in HIV-induced diseases. J Immunol. 1990; 145(12):4059-64. View

15.

Yasukawa K, Saito T, Fukunaga T, Sekimori Y, Koishihara Y, Fukui H . Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem. 1990; 108(4):673-6. DOI: 10.1093/oxfordjournals.jbchem.a123261. View

16.

Hirano T, Akira S, Taga T, Kishimoto T . Biological and clinical aspects of interleukin 6. Immunol Today. 1990; 11(12):443-9. DOI: 10.1016/0167-5699(90)90173-7. View

17.

Novick D, Engelmann H, Revel M, Leitner O, Rubinstein M . Monoclonal antibodies to the soluble human IL-6 receptor: affinity purification, ELISA, and inhibition of ligand binding. Hybridoma. 1991; 10(1):137-46. DOI: 10.1089/hyb.1991.10.137. View

18.

Ludwig H, Nachbaur D, Fritz E, Krainer M, HUBER H . Interleukin-6 is a prognostic factor in multiple myeloma. Blood. 1991; 77(12):2794-5. View

19.

Fernandez-Botran R, Vitetta E . Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J Exp Med. 1991; 174(3):673-81. PMC: 2118951. DOI: 10.1084/jem.174.3.673. View

20.

De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio G, Martini A . Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34(9):1158-63. DOI: 10.1002/art.1780340912. View